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Multidrug-Resistant
Shiga Toxin–
Producing
Escherichia coli
O118:H16 in Latin
America
To the Editor: We report the first
isolation of a multiple antimicrobial
drug–resistant strain of Shiga
toxin–producing  Escherichia coli
(STEC) O118:H16 from cattle in
Latin America. The strain was
isolated during a study of fecal STEC
in 205 healthy and 139 diarrheic cattle
on 12 beef farms in the state of São
Paulo, Brazil, in February 2000; one
case of STEC was found in a 1-
month-old calf with diarrhea. This
bovine STEC O118:H16 strain
showed resistance to eight
antimicrobial substances; the
following resistance (R)-genes were
detected: ampicillin (blaTEM1-like),
kanamycin and neomycin (aphA1),
streptomycin (strA/B), sulphame-
toxazol (sul2), tetracyclin (tet[A]),
trimethoprim (no dfrA1, A5, A7, A12,
A14, or A17), and trimethoprim/
sulphamethoxazol. The STEC O118:
H16 strain from Brazil was found to
be similar for virulence genes (Shiga
toxin 1 [stx1], intimin beta 1 [eae β1],
and EHEC-hemolysin [E-hlyA]) and
for antimicrobial drug resistance to
STEC O118:H16 strains, which were
isolated in different countries of
Europe (1). Beginning in 1986, STEC
O118:H16 was identified as an
emerging pathogen for calves and
humans in Belgium and Germany
(2–4). Cattle and human STEC
O118:H16 isolates were similar in
virulence attributes and antimicrobial
drug resistance and belonged to a
distinct genetic clone (1). Trans-
mission of these pathogens from
cattle to humans on farms was
observed (5).
Beginning in 1996, STEC
O118:H16 has become important as
an emerging pathogen in humans and
has been associated with bloody
diarrhea and hemolytic uremic
syndrome (2). Analysis of the
antimicrobial resistance profiles
showed that >96% of the European
STEC O118:H16 strains showed
resistance to one or more anti-
microbial drugs in contrast to the 10%
to 15% drug-resistant strains that
were detected among STEC
belonging to other serotypes (1,6,7).
STEC O118:H16 showing multi-
resistance in up to eight different
antimicrobial drugs predominated
among younger isolates, indicating
that drug resistance genes have
accumulated over time in STEC
O118:H16 strains. The frequency of
antimicrobial drug resistance in STEC
and Stx-negative E. coli in humans
and animals was compared in a study
by Schroeder et al. (8). Among human
clinical E. coli isolates, antimicrobial
resistance was less frequently
observed in STEC than in Stx-
negative strains, whereas in cattle,
antibiotic-resistant strains were found
at similar frequencies in both groups
of  E. coli. The relatively higher
frequency of antimicrobial-resistant
STEC in cattle was explained by the
use of antimicrobial drugs in cattle
production, whereas human infections
with STEC are generally not treated
with antibiotics (8). Cattle could thus
be an important source of new
emerging antibiotic-resistant STEC
strains such as O118:H16. 
The genetic basis of antimicrobial
resistance in STEC O118:H16 is
broad, including R-plasmids, inte-
grons, transposons, and chromo-
somally inherited drug-resistance
genes. Fluoroquinolone resistance has
also been acquired by some STEC
O118:H16 strains (1). The hetero-
genicity of antimicrobial drug–
resistance patterns, the increase of
multidrug-resistant strains over time1028 Emerging Infectious Diseases • Vol. 9, No. 8, August 2003
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of isolation, and the evidence for
multiple aquisition and genetic
location of R-determinants indicate
that strains belonging to the STEC
O118:H16 clone have a propensity to
acquire and accumulate R-genes. The
finding that multidrug-resistant STEC
O118:H16 is isolated from cattle in
South America indicates the global
spread of this new emerging EHEC
type.
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